The saga of Once Upon a Time in Shaolin, the one-of-a-kind Wu-Tang Clan album that Martin “pharma bro” Shkreli bought for ...

After several years of trying to obtain the paperwork, the U.S. Marshals Service finally gave a copy of the bill of sale and ...

After years of pursuing the unredacted records, Leopold finally got them last week. The government sold “Once Upon a Time in ...

There’s only one copy of Wu-Tang Clan’s unreleased 2015 album, Once Upon a Time in Shaolin. The rap group’s seventh studio project is also touted as the world’s most valuable album as Martin Shkreli, ...

When the Justice Department sold Once Upon a Time in Shaolin it concealed the sale price citing “trade secrets.” Now, after a ...

Shkreli's Turing Pharmaceuticals raised the price of an anti-parasitic drug from $13.50 to over $750 overnight, sparking outrage and prompting industry changes.

Martin Shkreli infamously jacked up the price of the life-saving drug Daraprim. Getty Images. In addition to the ban, Shkreli was found liable for $64.6 million in penalties related to his effort ...

Martin Shkreli, controversial drug CEO, arrested for fraud 02:32. For many social media users, Martin Shkreli's arrest Thursday on charges of securities fraud is cause for holiday cheer.

Martin Shkreli, former chief executive officer of Turing Pharmaceuticals and KaloBios Pharmaceuticals Inc, departs after a hearing at U.S. Federal Court in Brooklyn, New York, June 26, 2017.

Martin Shkreli, known for once hiking the price of a life-saving drug more than 4,000%, cannot return to the pharmaceutical industry after a federal appeals court on Tuesday upheld his lifetime ban.

Martin Shkreli, the disgraced former CEO and hedge fund manager derisively known as "Pharma Bro," was released early from a Pennsylvania federal prison Wednesday, according to multiple outlets.

Martin Shkreli, former CEO of Turing Pharmaceuticals, testified on Capitol Hill after hiking drug prices by more than 5,000 percent. Watch how lawmakers react to him invoking the Fifth Amendment.